ET-02
A topical reporting a six-fold hair-count increase in five weeks — from twenty-four men.
- Developed by
- Eirion Therapeutics
- Current phase
- Phase 1
- Indications
- Androgenetic alopecia
- Also known as
- RS-5441, ET02
- Last public activity
- Never
- Record confidence
- Medium
First tests in humans. Answers 'is it safe?', not 'does it work?'.
How it is meant to work
The sponsor describes it as restoring function to hair follicle stem cells that become inactive with age. Nothing further has been published, and this row does not elaborate beyond that description.
Why it matters
The headline number is extraordinary and the trial is tiny: 24 men across three US sites, primary endpoints safety and tolerability, five weeks of treatment. A six-fold increase in non-vellus hair count is measured from a low baseline, and the comparison the sponsor draws — more growth than four months of minoxidil — is not a head-to-head randomisation. A 150-patient phase 2 over six months is the study that would actually settle it.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results — Company release, January 2025